Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 10/20 | 0.81 |
| ▸ | FNTB | P49356 | 10/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cp-609754 SCHEMBL4277842 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL6583247 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL4299341 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL1644297 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| Cp-609754 SCHEMBL30481066 | 1.00 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL11947163 | 0.93 | FNTA (0.70) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL12021644 | 0.93 | FNTA (0.69) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL13573622 | 0.92 | FNTA (0.81) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL11955976 | 0.92 | FNTA (0.68) | FNTAFNTBCYP3A4RORC | |
| SCHEMBL11954234 | 0.91 | FNTA (0.67) | FNTAFNTBCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | NORTHWESTERN UNIVERSITY | 2023-06-29 | — | — | US | disclosed |
| CN-114306604-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-110325212-B | Farnesyl transferase inhibitors for use in methods of treating cancer | 库拉肿瘤学公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114107497-A | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2022-03-01 | — | — | CN | disclosed |
| CN-111214658-B | Methods of treating cancer patients with farnesyl transferase inhibitors | 库拉肿瘤学公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-107787373-B | Use of farnesyl transferase inhibitors for the treatment of cancer | 库拉肿瘤学公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-111214658-A | Methods of treating cancer patients with farnesyl transferase inhibitors | 库拉肿瘤学公司 | 2020-06-02 | — | — | CN | disclosed |
| WO-2019113269-A1 | METHODS OF TREATING CANCER PATIENTS WITH FARNESYLTRANSFERASE INHIBITORS | KURA ONCOLOGY, INC. (US) | 2019-06-13 | — | — | WO | disclosed |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010057028-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010056985-A9 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-08-19 | — | — | WO | disclosed |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010057028-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056985-A2 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2009151683-A2 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | LINK MEDICINE CORPORATION (US) | 2009-12-17 | — | — | WO | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230201183-A1 | METHODS TO SYNERGISTICALLY ENHANCE MULTIPLE CELLULAR PROTEOSTASIS PATHWAYS TO TREAT NEURODEGENERATION AND STORAGE DISEASES | HSPA5, GBA1, SNCA | FNTA 874/4885FNTB 1328/4885CYP3A4 4739/4885 |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | FNTA 4/4885FNTB 19/4885CYP3A4 3795/4885 |
| US-20100160372-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | FNTA 1/4885FNTB 2/4885CYP3A4 3236/4885 |
| US-20100331363-A1 | TREATMENT OF MITOCHONDRIAL DISORDERS USING A FARNESYL TRANSFERASE INHIBITOR | NLN, ACAT1, FH | FNTA 7/4885FNTB 8/4885CYP3A4 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.